Important Safety Information Prescribing Information Print This Page
Sign up for updates

Expect Results: Over 80% of men experienced an erection

Maintaining an erection is just as important as getting one. CAVERJECT (alprostadil for injection) can help with both. That's why you can feel confident when you ask your doctor about it. But that's not the only reason why. Here are a few more:

  • Worked over 80% of the time in a study for men with erectile dysfunction
  • Can work in as fast as 5 to 20 minutes
  • It is a local injection
    • Only 3% of men found it painful enough to stop using it

Who should not use CAVERJECT?

  • Any man who is allergic to alprostadil (the active ingredient) or anything else in CAVERJECT
  • Men who have been told by their healthcare provider not to have sex
  • Children, infants, and women
  • Men with conditions that might result in long-lasting erections that can damage the penis, such as:
    • Sickle cell anemia or sickle cell trait
    • Leukemia (white blood cell cancer)
    • Multiple myeloma (bone marrow cancer)
    • Abnormally shaped penis, a penis implant, or other problems of the penis
You’ll know if CAVERJECT works for you before you leave your healthcare provider’s office.


CAVERJECT is used to treat erectile dysfunction (ED) due to neurogenic, vasculogenic, psychogenic, or mixed etiology.


Important Safety Information

CAVERJECT should not be used in men hypersensitive to alprostadil, men with conditions that may predispose them to priapism (such as sickle cell anemia or trait, multiple myeloma or leukemia), men with anatomical deformities of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), men with penile implants, or men for whom sexual activity is inadvisable or is contraindicated.

CAVERJECT should not be used in women, children or newborns.

Patients should be instructed to immediately report to his physician any erection lasting 4 hours or longer. If unavailable, patient must seek immediate medical assistance.

CAVERJECT can cause penile fibrosis or Peyronie’s disease.

Use of Caverject in patients who take anticoagulants, such as warfarin or heparin, should be with precaution as they may have increased tendency for bleeding after Caverject injections.

The most common side effect of CAVERJECT® (alprostadil for injection) was penile pain, reported by 37% of patients in clinical studies. Other side effects were prolonged erection, penile fibrosis and injection site hematoma. To lower the risk of prolonged erections or priapism, Caverject should be titrated slowly to the lowest effective dose.

For Full Prescribing Information for CAVERJECT®, including Instructions for Use, please click here.